BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37698736)

  • 1. N
    Wang Y; Jin P; Wang X
    Apoptosis; 2024 Feb; 29(1-2):142-153. PubMed ID: 37698736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N
    Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
    Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N6-methyladenosine reader protein IGF2BP1 suppresses CD8 + T cells-mediated tumor cytotoxicity and apoptosis in colon cancer.
    Peng Y; Zhang Z; Yang G; Dai Z; Cai X; Liu Z; Yun Q; Xu L
    Apoptosis; 2024 Apr; 29(3-4):331-343. PubMed ID: 37848671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. circATAD2 mitigates CD8
    Zhang Z; Huo W; Li J
    Cancer Immunol Immunother; 2024 May; 73(7):130. PubMed ID: 38748254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumour immunity controlled through mRNA m
    Han D; Liu J; Chen C; Dong L; Liu Y; Chang R; Huang X; Liu Y; Wang J; Dougherty U; Bissonnette MB; Shen B; Weichselbaum RR; Xu MM; He C
    Nature; 2019 Feb; 566(7743):270-274. PubMed ID: 30728504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting N6-methyladenosine reader YTHDF1 with siRNA boosts antitumor immunity in NASH-HCC by inhibiting EZH2-IL-6 axis.
    Wang L; Zhu L; Liang C; Huang X; Liu Z; Huo J; Zhang Y; Zhang Y; Chen L; Xu H; Li X; Xu L; Kuang M; Wong CC; Yu J
    J Hepatol; 2023 Nov; 79(5):1185-1200. PubMed ID: 37459919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WTAP-induced N
    Liu QZ; Zhang N; Chen JY; Zhou MJ; Zhou DH; Chen Z; Huang ZX; Xie YX; Qiao GL; Tu XH
    Cancer Sci; 2024 Jun; 115(6):1749-1762. PubMed ID: 38508217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evodiamine impairs HIF1A histone lactylation to inhibit Sema3A-mediated angiogenesis and PD-L1 by inducing ferroptosis in prostate cancer.
    Yu Y; Huang X; Liang C; Zhang P
    Eur J Pharmacol; 2023 Oct; 957():176007. PubMed ID: 37611839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N
    Tang B; Bi L; Xu Y; Cao L; Li X
    Mol Biotechnol; 2023 Oct; ():. PubMed ID: 37817028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
    Front Immunol; 2021; 12():669750. PubMed ID: 34054840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pumilio1 regulates NPM3/NPM1 axis to promote PD-L1-mediated immune escape in gastric cancer.
    Wang H; Zhou Z; Zhang J; Hao T; Wang P; Wu P; Su R; Yang H; Deng G; Chen S; Gu L; He Y; Zeng L; Zhang C; Yin S
    Cancer Lett; 2024 Jan; 581():216498. PubMed ID: 38029539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N
    Wan W; Ao X; Chen Q; Yu Y; Ao L; Xing W; Guo W; Wu X; Pu C; Hu X; Li Z; Yao M; Luo D; Xu X
    Mol Cancer; 2022 Feb; 21(1):60. PubMed ID: 35197058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ELK1-mediated YTHDF1 drives prostate cancer progression by facilitating the translation of Polo-like kinase 1 in an m6A dependent manner.
    Li P; Shi Y; Gao D; Xu H; Zou Y; Wang Z; Li W
    Int J Biol Sci; 2022; 18(16):6145-6162. PubMed ID: 36439881
    [No Abstract]   [Full Text] [Related]  

  • 14. Methionine deficiency facilitates antitumour immunity by altering m
    Li T; Tan YT; Chen YX; Zheng XJ; Wang W; Liao K; Mo HY; Lin J; Yang W; Piao HL; Xu RH; Ju HQ
    Gut; 2023 Mar; 72(3):501-511. PubMed ID: 35803704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LRPPRC facilitates tumor progression and immune evasion through upregulation of m
    Wang H; Tang A; Cui Y; Gong H; Li H
    Front Immunol; 2023; 14():1144774. PubMed ID: 37063837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers.
    Yu ZZ; Liu YY; Zhu W; Xiao D; Huang W; Lu SS; Yi H; Zeng T; Feng XP; Yuan L; Qiu JY; Wu D; Wen Q; Zhou JH; Zhuang W; Xiao ZQ
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non-small-cell lung cancer.
    Tsuchiya K; Yoshimura K; Inoue Y; Iwashita Y; Yamada H; Kawase A; Watanabe T; Tanahashi M; Ogawa H; Funai K; Shinmura K; Suda T; Sugimura H
    Oncoimmunology; 2021; 10(1):1962656. PubMed ID: 34408926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination.
    Sun Z; Mai H; Xue C; Fan Z; Li J; Chen H; Huo N; Kang X; Tang C; Fang L; Zhao H; Han Y; Sun C; Peng H; Du Y; Yang J; Du N; Xu X
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrin α2 promotes immune escape in non-small-cell lung cancer by enhancing PD-L1 expression in exosomes to inhibit CD8 + T-cell activity.
    Jing H; Meng M; Ye M; Liu S; Cao X; Li K; Liu Y; Zhang J; Wu Y
    J Investig Med; 2024 Jan; 72(1):57-66. PubMed ID: 37804164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The m
    Diao H; Tan H; Hu Y; Wang R; Cai P; Huang B; Shao X; Yan M; Yin C; Zhang Y
    Pharmaceuticals (Basel); 2023 Jan; 16(2):. PubMed ID: 37259333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.